Risk factors
Nektar Therapeutics (NKTR) risk factors
Item 1A of every Nektar Therapeutics 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors51 risks4 new4 dropped9 reworded
FDA staffing cuts and government shutdowns pose new clinical trial delay threats. AI adoption introduces cybersecurity and IP infringement risks. Legal battles with Eli Lilly continue with ongoing pre-trial motions.
Filed Mar 13, 2026 - FY2024 10-K risk factors51 risks
Nektar Therapeutics faces heavy reliance on rezpegaldesleukin and partnership execution amid ongoing net losses totaling $119.0 million in 2024. Clinical trials, regulatory hurdles, single-source suppliers, and complex intellectual property litigation dominate the risk profile.
Filed Mar 14, 2025